Prenumeration
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Pharma Equity Group (“PEG” or “the Company”) announced on Monday, December the 29th 2025, a strategic update regarding progress within the Company’s pipeline projects RNX-051 and RNX-011, alongside revised revenue and earnings expectations for the 2025 financial year. The update also included clarification on accounting adjustments related to the Expected Credit Loss (ECL) model and a brief status update on discussions concerning the acquisition of Otiom.
Analyst Group’s view of the strategic update
Analyst Group believes that the advanced partnership discussions, combined with confirmation that regulatory and operational barriers to conducting international, multicentre studies have been addressed, support improved visibility around the execution pathway ahead of potential partnership outcomes during H1-26.
For RNX-011, we consider the refined development approach to be commercially rational and value-focused. The fact that the protocol has already received regulatory approval, and is now being adjusted based on partner feedback, suggests a partner-driven optimization aimed at maximizing differentiation and licensing attractiveness. While this may modestly extend timelines, it supports the quality and relevance of the future data package and may enhance long-term deal economics.
Against this backdrop, the downward revision of financial expectations for 2025 should be viewed as a strategic consequence of PEG’s decision to prioritize long-term licensing value over near-term monetization. While PEG remains reliant on external financing in the near term, Analyst Group assesses that successful conversion of pipeline progress into licensing agreements, particularly for RNX-051, remains the key value driver in the short term. In combination with the Company’s MedTech initiatives, such as the LOI to acquire Otiom A/S, PEG’s strategy reflects a broader Life Science approach that spans both clinical development and more commercially oriented businesses, supporting a more diversified portfolio.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on Pharma Equity Group. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.